Evidence engine

Every number, with its proof.

The research behind our charts and tools: what was studied, in how many people, how big the effect was and how certain we can be. Filter it, sort it, and ask Biongevity SI to explain any card.

GRADE-ratedSources linkedUpdated as trials publish
0
Evidence cards
0
Studies
0.0M
People studied
0
High-certainty
HeartHigh

Lowering blood pressure

Each 10 mmHg lower systolic pressure cuts major cardiovascular events by about 20%.

123
studies
614k
people
2016
published
0.25×lower risk ← 1 → higher risk6×
0.80 (95% CI 0.77–0.83) · per 10 mmHg
20% fewer major cardiovascular events

Why high: Large randomised evidence, consistent across groups.

Meta-analysis of randomised trials · Ettehad et al., Lancet 2016

Cardiology
HeartHigh

Lowering LDL cholesterol

Each 1 mmol/L lower LDL cuts major heart and stroke events by about a fifth.

26
studies
170k
people
2010
published
0.25×lower risk ← 1 → higher risk6×
0.78 (95% CI 0.76–0.80) · per 1 mmol/L LDL
22% fewer major vascular events

Why high: Many large randomised trials, consistent and precise.

Meta-analysis of randomised trials · Cholesterol Treatment Trialists' Collaboration, Lancet 2010

Cardiology
SupplementsHigh

Vitamin D supplements

In generally healthy adults, vitamin D did not lower cancer or cardiovascular events.

1
study
26k
people
2019
published
0.25×lower risk ← 1 → higher risk6×
0.97 (95% CI 0.85–1.12) · cardiovascular events
No clear benefit for heart events (cancer HR 0.96)

Why high: Large, well-run randomised trial — a useful 'no effect' result.

Randomised trial · Manson et al., NEJM 2019 (VITAL)

HeartModerate

Usual blood pressure and risk

From 115 mmHg upward, every 20 mmHg higher systolic pressure roughly doubles vascular death risk (ages 40–69).

61
studies
1.0M
people
2002
published
≈2× vascular death per +20 mmHg

Why moderate: Observational, but very large with a strong dose–response.

Meta-analysis of prospective cohorts · Prospective Studies Collaboration, Lancet 2002

Cardiology
BiomarkersModerate

Lipoprotein(a)

Higher Lp(a) is linked with more coronary disease; it is largely inherited, so one test is usually enough.

36
studies
127k
people
2009
published
0.25×lower risk ← 1 → higher risk6×
1.13 (95% CI 1.09–1.18) · per 3.5× higher Lp(a)
13% higher coronary risk per 3.5-fold higher Lp(a)

Why moderate: Observational, supported by genetic (Mendelian randomisation) studies.

Meta-analysis of prospective studies · Emerging Risk Factors Collaboration, JAMA 2009

Cardiology
LifestyleModerate

Stopping smoking

Stopping by age 30 avoids almost all the excess risk; stopping at 40, 50 or 60 still gains about 9, 6 or 3 years.

1
study
34k
people
2004
published
Up to ≈10 years of life regained

Why moderate: Very long follow-up with a large, consistent effect.

Prospective cohort, 50 years of follow-up · Doll et al., BMJ 2004

SupplementsModerate

High-dose EPA (omega-3, prescription)

In people with high triglycerides on statins, high-dose purified EPA lowered cardiovascular events.

1
study
8k
people
2019
published
0.25×lower risk ← 1 → higher risk6×
0.75 (95% CI 0.68–0.83) · icosapent ethyl vs placebo
25% fewer cardiovascular events

Why moderate: One large trial; debate about the mineral-oil placebo. Not the same as over-the-counter fish oil.

Randomised trial · Bhatt et al., NEJM 2019 (REDUCE-IT)

Cardiology
LifestyleModerate

Mediterranean diet

A Mediterranean diet with extra-virgin olive oil or nuts lowered major cardiovascular events.

1
study
7k
people
2018
published
0.25×lower risk ← 1 → higher risk6×
0.69 (95% CI 0.53–0.91) · olive-oil arm vs control
≈30% fewer major cardiovascular events

Why moderate: Single large trial, re-analysed after randomisation issues.

Randomised trial · Estruch et al., NEJM 2018

Nutrition
LifestyleLow

Short sleep

Consistently sleeping less than about 6–7 hours is linked with higher mortality.

16
studies
1.4M
people
2010
published
0.25×lower risk ← 1 → higher risk6×
1.12 (95% CI 1.06–1.18) · short vs 7–8 h
12% higher mortality (long sleep: 30%)

Why low: Observational; sleep may reflect other illness.

Meta-analysis of prospective cohorts · Cappuccio et al., Sleep 2010

BiomarkersLow

hs-CRP (inflammation)

Higher CRP is associated with more coronary heart disease.

54
studies
160k
people
2010
published
0.25×lower risk ← 1 → higher risk6×
1.37 (95% CI 1.27–1.48) · per 1 SD higher log CRP
37% higher coronary risk per SD

Why low: Observational; association weakens after adjustment for other risk factors.

Meta-analysis of prospective cohorts · Emerging Risk Factors Collaboration, Lancet 2010

LifestyleLow

Five healthy habits

Never smoking, healthy weight, 30+ minutes of activity, moderate alcohol and a quality diet add years.

2
studies
123k
people
2018
published
+14.0 years (women) and +12.2 years (men) of life expectancy at 50

Why low: Observational; US health professionals.

Two large prospective cohorts · Li et al., Circulation 2018

LifestyleLow

Cardiorespiratory fitness

Low fitness carries a mortality risk comparable to or greater than smoking or diabetes.

1
study
122k
people
2018
published
0.25×lower risk ← 1 → higher risk6×
5.04 (95% CI 4.10–6.20) · lowest vs elite fitness
≈5× higher mortality, lowest vs elite

Why low: Single-centre, observational; strong gradient.

Retrospective cohort (treadmill testing) · Mandsager et al., JAMA Network Open 2018

LifestyleLow

Genes vs lifestyle

A favourable lifestyle is linked with about half the coronary risk, even with high genetic risk.

4
studies
56k
people
2016
published
0.25×lower risk ← 1 → higher risk6×
0.54 (95% CI 0.47–0.63) · favourable vs unfavourable
46% lower relative coronary risk

Why low: Observational; consistent across genetic risk groups.

Four prospective cohorts and studies · Khera et al., NEJM 2016

LifestyleLow

Daily steps

More daily steps are linked with lower mortality, levelling off around 6,000–8,000 (60+) and 8,000–10,000 (under 60).

15
studies
47k
people
2022
published
0.25×lower risk ← 1 → higher risk6×
0.47 (95% CI 0.39–0.57) · highest vs lowest quartile
≈53% lower mortality in the most active quarter

Why low: Observational with a clear dose–response; device-measured steps.

Meta-analysis of prospective cohorts · Paluch et al., Lancet Public Health 2022

GRADE rates how certain the evidence is: High (further research is very unlikely to change it) to Very low. Summaries are curated and paraphrased from the cited papers — always check the original. Last reviewed October 2026.

Evidence into a plan.

Book a consultation online, or message us on WhatsApp and a coordinator will reply during clinic hours.

or call 403-250-2221
Your next step
Popular next steps. Browse a little and these adapt to you, on your device.
Book now